Entera Bio (NASDAQ:ENTX) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Entera Bio (NASDAQ:ENTX) in a report published on Monday,Benzinga reports. The firm currently has a $10.00 price target on the stock.

Entera Bio Stock Down 1.2 %

ENTX stock opened at $1.70 on Monday. Entera Bio has a twelve month low of $0.52 and a twelve month high of $3.35. The firm has a market cap of $60.83 million, a PE ratio of -6.54 and a beta of 1.58. The business has a 50 day moving average of $1.87 and a 200 day moving average of $1.92.

Entera Bio (NASDAQ:ENTX) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). The company had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. On average, research analysts expect that Entera Bio will post -0.23 earnings per share for the current fiscal year.

Institutional Trading of Entera Bio

A hedge fund recently bought a new stake in Entera Bio stock. Virtu Financial LLC purchased a new position in Entera Bio Ltd. (NASDAQ:ENTX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 22,040 shares of the company’s stock, valued at approximately $37,000. Institutional investors own 14.11% of the company’s stock.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.